Tag: Johnson & Johnson

Johnson & Johnson: XARELTO Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on JNJ.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots – and similar…

Johnson & Johnson: New Evidence Highlights Need for Interventions to Improve Outcomes for Patients Wth Major Depressive Disorder and Suicide Ideation or Attempt

Data presented at the American Psychiatric Association 2019 Meeting suggest a low rate of psychiatric care received by adult patients with MDD before suicide ideation or attempt diagnosis Originally Published by Johnson & Johnson. Additional Data Show Patients Have a High Risk of Hospital Readmission or Subsequent Emergency Department Visit…

burnout, doctors, nurses, Johnson & Johnson, care

Johnson & Johnson: Caring for Care Providers: An Innovative Way to Help Address the Growing Crisis of Doctor and Nurse Burnout

Up to 70% of nurses and nearly 55% of physicians report symptoms of burnout, which costs workplaces millions of dollars a year due to lost productivity and employee turnover and absenteeism—and impacts patient quality of care. But the CareAdvantage program is poised to help. By Kristen Mascia Originally Published by…

Johnson & Johnson: From Aha! Moment to FDA Approval: The Fascinating Story Behind a New Treatment for Bladder Cancer

We retrace the 22-year journey it took to bring a potentially life-changing treatment for an aggressive form of the disease to patients who may benefit most. Originally Published by Johnson & Johnson. By Hallie Levine It’s the sixth most common cancer, yet treatment options formetastatic bladder cancer are limited. But now, there’s…

Janssen and MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases

Originally Published by Johnson & Johnson. The Janssen Pharmaceutical Companies of Johnson & Johnson announced a worldwide collaboration and license agreement with MeiraGTx Holdings plc (NASDAQ:MGTX), a clinical-stage gene therapy company, to develop, manufacture and commercialize its clinical stage inherited retinal disease portfolio, including leading product candidates for achromatopsia (ACHM)…